Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Hasnain, Mehrul
Fredrickson, Sonja K.
Vieweg, W. Victor R.
and
Pandurangi, Anand K.
2010.
Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics.
Current Diabetes Reports,
Vol. 10,
Issue. 3,
p.
209.
Mitchell, Alex J
and
Dinan, Timothy G
2010.
Schizophrenia: a multisystem disease?.
Journal of Psychopharmacology,
Vol. 24,
Issue. 4_suppl,
p.
5.
2010.
Current awareness: Pharmacoepidemiology and drug safety.
Pharmacoepidemiology and Drug Safety,
Vol. 19,
Issue. 8,
p.
i.
De Hert, M.
Vancampfort, D.
Correll, C. U.
Mercken, V.
Peuskens, J.
Sweers, K.
van Winkel, R.
and
Mitchell, A. J.
2011.
Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation.
British Journal of Psychiatry,
Vol. 199,
Issue. 2,
p.
99.
Maayan, Lawrence
and
Correll, Christoph U.
2011.
Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents.
Journal of Child and Adolescent Psychopharmacology,
Vol. 21,
Issue. 6,
p.
517.
Tek, Cenk
Ratliff, Joseph C.
and
Chwastiak, Lydia
2011.
Pharmacological Treatment of Obesity.
Psychiatric Annals,
Vol. 41,
Issue. 10,
p.
489.
de Hert, M.
Dobbelaere, M.
Sheridan, E.M.
Cohen, D.
and
Correll, C.U.
2011.
Efectos adversos metabólicos y endocrinos de los antipsicóticos de segunda generación en niños y adolescentes: una revisión sistemática de ensayos aleatorizados, controlados con placebo y guías de práctica clínica.
Psiquiatría Biológica,
Vol. 18,
Issue. 3,
p.
89.
Fraguas, David
Correll, Christoph U.
Merchán-Naranjo, Jessica
Rapado-Castro, Marta
Parellada, Mara
Moreno, Carmen
and
Arango, Celso
2011.
Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons.
European Neuropsychopharmacology,
Vol. 21,
Issue. 8,
p.
621.
Phutane, Vivek H.
Tek, Cenk
Chwastiak, Lydia
Ratliff, Joseph C
Ozyuksel, Banu
Woods, Scott W.
and
Srihari, Vinod H.
2011.
Cardiovascular risk in a first-episode psychosis sample: A ‘critical period’ for prevention?.
Schizophrenia Research,
Vol. 127,
Issue. 1-3,
p.
257.
De Hert, M.
Dobbelaere, M.
Sheridan, E.M.
Cohen, D.
and
Correll, C.U.
2011.
Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice.
European Psychiatry,
Vol. 26,
Issue. 3,
p.
144.
Cubells, Joseph F.
2011.
Concerns Over Participant Suicides Prematurely Abort a Clinical Trial of Potentially Significant Impact on Public Health: How Will We Make Progress in Timid Times?.
Current Psychiatry Reports,
Vol. 13,
Issue. 2,
p.
80.
Shin, Jinah K.
Barron, Charles T.
Chiu, Ya-Lin
Hyun Jang, Sou
Touhid, Shihab
and
Bang, Heejung
2012.
Weight Changes and Characteristics of Patients Associated with Weight Gain during Inpatient Psychiatric Treatment.
Issues in Mental Health Nursing,
Vol. 33,
Issue. 8,
p.
505.
de Hoogd, Sjoerd
Overbeek, Wieske A.
Heerdink, Eibert R.
Correll, Christoph U.
de Graeff, Elisabeth R.
and
Staal, Wouter G.
2012.
Differences in Body Mass Index z-Scores and Weight Status in a Dutch Pediatric Psychiatric Population With and Without Use of Second-Generation Antipsychotics.
Journal of Child and Adolescent Psychopharmacology,
Vol. 22,
Issue. 2,
p.
166.
Ben Amor, Leila
2012.
Antipsychotics in pediatric and adolescent patients: A review of comparative safety data.
Journal of Affective Disorders,
Vol. 138,
Issue. ,
p.
S22.
De Hert, Marc
Detraux, Johan
van Winkel, Ruud
Yu, Weiping
and
Correll, Christoph U.
2012.
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
Nature Reviews Endocrinology,
Vol. 8,
Issue. 2,
p.
114.
Pai, Nagesh
Deng, Chao
Vella, Shae-Leigh
Castle, David
and
Huang, Xu-Feng
2012.
Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: Temporally based hypothesis.
Asian Journal of Psychiatry,
Vol. 5,
Issue. 4,
p.
315.
Mitchell, Alex J.
Delaffon, Vijay
and
Lord, Oliver
2012.
Let's get physical: improving the medical care of people with severe mental illness.
Advances in Psychiatric Treatment,
Vol. 18,
Issue. 3,
p.
216.
Ellenbroek, Bart A.
2012.
Psychopharmacological treatment of schizophrenia: What do we have, and what could we get?.
Neuropharmacology,
Vol. 62,
Issue. 3,
p.
1371.
Batstra, Laura
and
Frances, Allen
2012.
Diagnostic Inflation.
The Journal of Nervous and Mental Disease,
Vol. 200,
Issue. 6,
p.
474.
De Hert, Marc
Yu, Weiping
Detraux, Johan
Sweers, Kim
van Winkel, Ruud
and
Correll, Christoph U.
2012.
Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder.
CNS Drugs,
Vol. 26,
Issue. 9,
p.
733.